742105
Last Update Posted: 2018-09-25
Recruiting has ended
All Genders accepted | 20 Years + |
18 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan
This study will confirm safety and tolerability and determine the MTD of BGT226 in Japanese patients with advanced solid tumor.
Eligibility
Relevant conditions:
Cancer
Solid Tumor
Advanced Solid Tumor
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov